This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hayes, R. P. Articles by McHorney, C. A. Search for Related Content PubMed PubMed Citation Articles by Hayes, R. P. Articles by McHorney, C. A. Social Bookmarking                         What's this?

Understanding Diabetes Medications From the Perspective of Patients With Type 2 Diabetes

Prerequisite to Medication Concordance

From Global Health Outcomes Research, Eli Lilly & Company, Indianapolis, Indiana (Dr Hayes, Dr Bowman); Division of Biostatistics, Department of Medicine, Indiana University School of Medicine, Indianapolis (Dr Monahan); Division of Endocrinology & Metabolism, Indiana University School of Medicine, Indianapolis (Dr Marrero); and Outcomes Research & Management, Merck & Company, West Point, Pennsylvania (Dr McHorney).

Correspondence to Clarice (Risa) Hayes, PhD, Lilly Corporate Center, DC1833, Indianapolis, IN 46285 (hayes_clarice{at}lilly.com).

Purpose

The purpose of this qualitative study was to explore diabetes medication experiences of patients with type 2 diabetes.

Methods

Study participants were recruited through newspaper advertisements and letters from primary and specialty clinics in Indianapolis, Indiana. The same professional facilitator conducted 18 focus groups (7 male, 11 female) at a Veteran Affairs facility in Indianapolis, Indiana. Participants were 138 socioeconomically diverse individuals with type 2 diabetes (68% female, 74% 50 years old, 61% non-Hispanic Caucasian). Participants were on a variety of diabetes medication regimens (61% injectable insulin monotherapy or in combination with orals). Content analysis of focus group transcripts was used to establish themes.

Results

Three major themes emerged across the focus groups: (1) the inconvenience and inflexibility of the timing and frequency of administration of many diabetes treatments on participants' lives, (2) the desire to avoid injections and/or insulin therapy, and (3) the physical and emotional side effects of diabetes medications. Assuming equivalent effectiveness of 2 medications, participants would weigh the convenience and flexibility, route of administration, side effects, and cost of the medications to arrive at a treatment preference. Participants believed they currently had no opportunity to express their treatment preference to their health care provider.

Conclusions

The best therapeutic option for a patient with type 2 diabetes will be one that is clinically effective and consistent with the patient's needs and preferences. The challenge for diabetes educators is to support patients in articulating and incorporating their needs and preferences into the treatment decision-making process.

The Diabetes Educator, Vol. 32, No. 3, 404-414 (2006)
DOI: 10.1177/0145721706288182


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Wolzt, A. de la Pena, P.-Y. Berclaz, F. S. Tibaldi, J. R. Gates, and D. B. Muchmore AIR Inhaled Insulin Versus Subcutaneous Insulin: Pharmacokinetics, glucodynamics, and pulmonary function in asthma Diabetes Care, April 1, 2008; 31(4): 735 - 740. [Abstract] [Full Text] [PDF]